



I. Skin Cancers

a. Epidemiologic/Correlative

UCI 09-17 Biology of Human Melanocytes and Keratinocytes (Meyskens)

UCI 14-25 Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (Nelson)

UCI 16-01 -Suspended- (PAINT)-Pathway Analyses for Individualized Network Therapeutics for Cancer (Nelson)

b. Prevention

UCI 14-92 Phase IV Study of Daylight Photodynamic Therapy with Aminolevulinic Acid for Actinic Keratoses (Zachary)

c. Screening/Diagnostic

UCI 11-30 Skin imaging with Technologies in Development (Kelly)

UCI 13-13 Pilot study on in-vivo non-invasive skin imaging using multiphoton microscopy and multispectral imaging (Kelly)

UCI 15-08 Spectral comparison between Spatially Modulated Quantitative Spectroscopy (SMoQS) and Polarization Sensitive Hyperspectral Multimode Dermoscopy for the purpose of skin compositional analysis (Kelly)

II. Cutaneous Melanoma

a. Screening/Diagnostic

UCI 16-82 DecisionDx-Melanoma 31-Gene Expression Profile Clinical Impact Study #4 (Yamamoto)

UCI 14-05 Multi-Center Evaluation of Oncogenesis via Spectral Analysis with the Melanoma Advanced Imaging Dermoscope (mAID) (Linden/Kelly)

b. Metastatic: Unresectable Not Previously Treated

i. BRAF Mutated Only

UCI 16-92
A Phase III, Double-Blinded, Randomized, Placebo-Controlled Study of Atezolizumab Plus Cobimetinib and Vemurafenib versus Placebo plus Cobimetinib and Vemurafenib in Previously Untreated BRAF V600 Mutation-Positive Patients with Metastatic or Unresectable Locally Advanced Melanoma (Fruehauf)

UCI 17-09
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients with Unresectable or Metastatic BRAF V600 Mutant Melanoma (Fruehauf)

UCI 17-73 Pending**
A Sequential 2-arm, Open-label Phase 1 Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib on the Pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan Administered in a Cocktail Approach and on the Pharmacokinetics of Rosuvastatin in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors (Fruehauf)

ii. BRAF Wild-Type Only

UCI 16-102
A Phase III, Open-Label, Multicenter, Two Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab versus Pembrolizumab in Patients with Previously Untreated Advanced BRAFV600 Wild-Type Melanoma (Fruehauf)

III. Cutaneous T-Cell Lymphoma (CTCL)

b. Screening/Diagnostic

UCI 16-37 Pending**

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome (Pinter-Brown)

a. Therapeutic

UCI 16-45

A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K δ/γ inhibitor, in Patients with Relapsed or Refractory T-cell Lymphoma (Pinter-Brown)

UCI 16-46

A Phase 1 Dose-Ranging Study to Investigate the Safety, Tolerability and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects with Various Lymphomas and Leukemias (Pinter-Brown)

IV. Miscellaneous & Phase 1 Clinical Trials

ECOG-EAY131

Molecular Analysis for Therapy Choice (MATCH) (Bota)

UCI 16-96

A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (Ou)

SWOG S1609

(CIRB) DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Bota)

UCI 17-50 Pending**

A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (Ou)

UCI 17-58 Pending**

Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas (Pinter-Brown)